Puberty Blockers Clinical Trial

Graham Stringer Excerpts

Monday 23rd March 2026 Westminster Hall

[Jamie Stone]

I thank the hon. Member for her intervention, but she will understand that it is my job as Chairman of the Petitions Committee to present a fair description of both sides of the discussion, which is what I hope to do.

James Esses, who started the petition, is a psychotherapist, and he impressed on me the benefit that good psychiatric intervention could have, without medicalisation. Puberty, he argued, is rarely a picnic for anyone—it can be confusing, uncomfortable, and sometimes miserable—but it is an essential developmental stage, and suppressing it pharmacologically could alter physical and cognitive development in ways we do not yet fully grasp. His argument is not to remove care for children experiencing gender incongruence, but to focus efforts on careful psychological support.

Others question the trial’s purpose, noting that puberty blockers have already been paused for new NHS patients with gender incongruence, following concerns about safety. They fear that authorising a new trial implies a level of confidence that the evidence base does not yet justify, arguing that enough data exists to recognise the potential harms, from reduced bone density to uncertain impact on brain development. Continuing could erode the safeguards that protect young people.

[Graham Stringer (Blackley and Middleton South) (Lab)]

The hon. Member is making great efforts to be balanced in his presentation on behalf of the Petitions Committee. He says this is a complex area, but surely it is actually quite simple: we should not be experimenting on children, particularly as we cannot do double-blind experiments. Those are two fundamental reasons why these so-called experiments should not go ahead.

[Jamie Stone]

I note the sincerity with which the hon. Gentleman makes his remarks. There is the legal and ethical question of whether a child can ever truly consent to something like this.